牛牛AI助理已提取核心訊息
Cardio Diagnostics Holdings, Inc. (Cardio) has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 26, 2024, for a proposed public offering of securities. The registration statement includes common stock, preferred stock, warrants, units, and subscription rights, with the potential to raise up to $17.0 million. Cardio, a company focused on developing products for cardiovascular diseases leveraging AI-driven genetic-epigenetic technology, has not declared dividends historically and has incurred net losses in recent years. The company plans to use the net proceeds for general corporate purposes, including working capital. Cardio's common stock and public warrants are listed on the Nasdaq Capital Market under the symbols 'CDIO' and 'CDIOW' respectively. The offering will be made through an 'at...Show More
Cardio Diagnostics Holdings, Inc. (Cardio) has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 26, 2024, for a proposed public offering of securities. The registration statement includes common stock, preferred stock, warrants, units, and subscription rights, with the potential to raise up to $17.0 million. Cardio, a company focused on developing products for cardiovascular diseases leveraging AI-driven genetic-epigenetic technology, has not declared dividends historically and has incurred net losses in recent years. The company plans to use the net proceeds for general corporate purposes, including working capital. Cardio's common stock and public warrants are listed on the Nasdaq Capital Market under the symbols 'CDIO' and 'CDIOW' respectively. The offering will be made through an 'at the market offering' agreement with Craig-Hallum Capital Group LLC, allowing sales directly into the market at varying prices. The company's management will have broad discretion over the use of the net proceeds, and there is no guarantee of the minimum amount raised. The offering may result in dilution for current shareholders and the stock may become the target of a 'short squeeze' due to market volatility.
Cardio Diagnostics Holdings, Inc.（Cardio）已於2024年1月26日向美國證券交易委員會（SEC）提交了S-3表格，要求進行證券公開發行。註冊聲明包括普通股、優先股、認股權證、單位和認購權，可能籌集高達1700萬美元的資金。Cardio是一家專注於利用人工智能驅動的遺傳表觀遺傳學技術開發心血管疾病產品的公司，該公司歷來沒有宣佈分紅，近年來也出現了淨虧損。該公司計劃將淨收益用於一般公司用途，包括營運資金。Cardio的普通股和公開認股權證分別在納斯達克資本市場上市，代碼分別爲 “CDIO” 和 “CDIOW”。此次發行將通過與Craig-Hallum Capital Group LLC簽訂的 “市場發行” 協議進行，允許以不同的價格直接向市場銷售。公司的管理層將對淨收益的使用擁有廣泛的自由裁量權，並且無法保證最低籌集金額。此次發行可能會導致現有股東稀釋，由於市場波動，該股可能成爲 “空頭擠壓” 的目標。
Cardio Diagnostics Holdings, Inc.（Cardio）已於2024年1月26日向美國證券交易委員會（SEC）提交了S-3表格，要求進行證券公開發行。註冊聲明包括普通股、優先股、認股權證、單位和認購權，可能籌集高達1700萬美元的資金。Cardio是一家專注於利用人工智能驅動的遺傳表觀遺傳學技術開發心血管疾病產品的公司，該公司歷來沒有宣佈分紅，近年來也出現了淨虧損。該公司計劃將淨收益用於一般公司用途，包括營運資金。Cardio的普通股和公開認股權證分別在納斯達克資本市場上市，代碼分別爲 “CDIO” 和 “CDIOW”。此次發行將通過與Craig-Hallum Capital Group LLC簽訂的 “市場發行” 協議進行，允許以不同的價格直接向市場銷售。公司的管理層將對淨收益的使用擁有廣泛的自由裁量權，並且無法保證最低籌集金額。此次發行可能會導致現有股東稀釋，由於市場波動，該股可能成爲 “空頭擠壓” 的目標。
有用
沒用